The global microcarriers market was valued at USD 1.27 billion in 2021 and it is predicted to surpass around USD 3.32 billion by 2030 with a CAGR of 11.27% from 2022 to 2030.
The growth of the market is driven by the rising demand of cell-cultured products, the growing burden of diseases worldwide, constant investments for intensive R&D activities to identify and develop new treatments for rare disorders, and the continuous developments in technologies employed in advanced research such as cell-biology.4
Amidst the COVID-19 pandemic, the market witnessed a positive growth. The continuous strive of scientist and researchers to find and develop vaccines for the SARS-CoV2 virus resulted in scaling up of R&D efforts by both healthcare companies and academic institutes. The increased research activities, huge funding, and growing demand of therapeutic products resulted in the growth of the market. Moreover, development of viral vectors based vaccines requires efficient production of viruses which is possible using microcarriers cell-culture. For instance, scientists from University of Copenhagen demonstrated in their research article published in June 2021 that SARS-CoV2 virus was efficiently produced in Vero cells in a single-use bioreactors packed with carrier beads. Findings like these have boosted the COVID-19 vaccine production further propelling market growth.
Moreover, the marketspace is rapidly expanding owing to the high usage of microcarriers as matrix for adherent cell manufacturing and these small spherical beads are used across all scales of commercial production. The increasing demand of innovative therapeutic options such as cell and gene therapy, viral vaccines, and monoclonal antibodies for treatment of malignant and rare diseases has resulted in increase in the biopharmaceutical production capacities. For example, Pfizer Inc., announced in December 2021 that it has invested USD 68.5 million and opened a new facility in North Carolina, USA. With the expansion the company is focused on enhancing its gene therapy capabilities and clinically develops its portfolio for hemophilia A and B, DMD (Duchenne muscular dystrophy), ALS (amyotrophic lateral sclerosis) and many more neurologic, endocrine as well as metabolic diseases. Such increased investments for development of biopharmaceuticals and regenerative medicines are expected to propel the market growth.
Furthermore, cell-biology based research involves exhaustive R&D for developing new therapies. But these efforts require investments for cell lines, media, equipment and other related products for microcarriers culture and thus requires huge influx of money. Institutes and emerging players with budget constraints will limit the cell based research for therapeutics development. Hence, it will decrease the adoption of cell-culture products and restrain the growth. However, government initiatives for novel drug production and collaboration & partnerships with key players can offer investment relief and enhance the market growth.
Scope of The Report
|Market Size in 2021|
|Revenue Forecast by 2030|
|Growth rate from 2022 to 2030||CAGR of%|
|Forecast Period||2022 to 2030|
|Segmentation||Consumables, application, end-user, region
Microcarrier beads contributed to the largest market share of 64.1% in the 2021 microcarriers marketspace. The never-ceasing use of microcarrier beads during cell culture contributes to the highest revenue generation in the market. Increased cell biology research, growing demand for regenerative medicines and biopharmaceuticals, and the presence of various microcarrier beads that can be employed for different purposes attributed to the significant market growth.
Vast product offerings by key market players and continuous developments in microcarrier technology have led to the creation of lucrative opportunities and resulted in the launch of novel products. Companies like Sartorius AG are offering microcarrier beads that are animal component free as well as animal protein coated for adherent cell culture. Thus, microcarrier beads can be extensively used during numerous processes and research purposes which further increases the segment’s revenue generation. Microcarriers markets have also observed exhaustive use of media & reagents during cell-based research as well as manufacturing processes. Continuous use, replenishment, and various applications of microcarrier consumables majorly drive market growth.
The biopharmaceutical production segment captured the largest market share of 72.63% in 2021. The dominance of this segment is driven by key factors such as the increasing incidence of cancer and growing cases of infectious diseases & genetic disorders which has resulted in growing demand for producing safe & effective medicines or treatments. To meet the growing demand, biopharmaceutical companies are expanding their capacities and product offerings. For instance, in August 2022, Celltrion Inc. a Korea-based healthcare company announced that it received the approval of the European Commission for its bevacizumab biosimilar, Vegzelma for the treatment of some types of cancer. With this 3rd biosimilar approval, the company has expanded its oncology care portfolio for use in Europe.
Furthermore, the rising adoption of therapeutic biopharmaceuticals and regulatory support is also boosting the microcarriers market. For example, the US FDA has approved 39 biosimilars till September 2022. These approvals have demonstrated that safe and effective biosimilars can penetrate market and improve the access to care by offering multiple medication options at potentially lower costs. Additionally, the unprecedented COVID-19 pandemic has driven the need of effective treatment and urged researchers & manufacturers to develop novel healthcare products. The vaccine production for SARS CoV-2 virus has positively impacted the microcarriers market by employing single-use and microcarrier beads packed bioreactors.
Based on end-user, the pharmaceutical and biotechnology companies segment dominated the market and accounted for a revenue share of 43.57% in 2021. Multiple drug development programs, the growing cell therapy industry, increased investments in R&D, and supportive government regulations are majorly driving the growth of this segment. Moreover, the rising awareness about the benefits of cell-based products is driving biologics production by these companies and resulting in the global expansion of capabilities. For instance, in August 2022, Thermo Fisher Scientific, Inc., stated that it has expanded its facility in Grand Island, New York. The USD 76 million expansion increases the company’s capacity to produce cell culture media for manufacturing vaccines and biologics.
Furthermore, with continuous development in bioprocessing capabilities and advanced equipment, pharmaceutical and biotechnology companies are trying to meet the demand for cell-based products. In addition, employing microcarriers during bio-manufacturing eases the culturing of cells and the manufacturing process and also improves the yield due to a 3D environment. The constant progress by research settings, collaboration with academic institutes, and outsourcing to CROs/ CMOs for faster market entry speed will increase the adoption of microcarriers during cell culture.
North America dominated the microcarriers market and accounted for a revenue share of 40.78% in 2021. The rising cases of chronic and infectious diseases, increasing awareness of personalized medicines, better healthcare infrastructure, and reimbursement models, presence of key market players, and intensive R&D activities have boosted the region’s growth. Moreover, regulatory support for biopharmaceuticals and regenerative medicines is also driving the market entry of new cell-based therapies. For instance, the U.S. FDA predicts by 2025 it’ll be approving around 10 to 20 products of cell and gene therapy each year due to the current clinical success rates and the product pipeline. Also, as per a fact sheet in November 2021, the US FDA stated that there are about 621 biologics products that are licensed. Continuous product approvals and the growth of the bio-manufacturing market will drive the presence of microcarriers market in North America.
In Asia Pacific, the market is estimated to observe the fastest growth during the forecast period. The government incentives for vaccine production and low operation & labor costs drive multiple research settings in the region. Additionally, the Asia Pacific region is driven by the domestic demand of biologics as well as growing economies and also has the highest geriatric population. Furthermore, many local Asian and international companies are developing number of the world’s new bioprocessing facilities in this region. For instance, in October 2021, Singapore witnessed the expansion of Lonza’s facility for mammalian services. The CDMO has added this capacity to support growing manufacturing & analytical needs. This preliminary focus on the development of biosimilar monoclonal antibodies (mAbs), as well as vaccines due to various government immunization initiatives, will drive the adoption of microcarriers in the region during the years to come.